IMFINZI 50 mg/mL concentrate for solution for infusion clinical trials
13 indexed studies · 7 currently recruiting
- AuthorisedTherapeutic exploratory (Phase II)
In-vivo fluorescence molecular bronchoscopy of durvalumab-680LT in patients with unresectable stage III NSCLC after chemoradiation - PulmoPrint
This study tests a new imaging technique for people with stage 3 non-small cell lung cancer. Doctors give a glowing version of the immunotherapy drug durvalumab before a camera check of the lungs. The goal is to see if tumours light up clearly to help improve future treatment.
For: Unresectable stage III non-small cell lung cancerNetherlands - AuthorisedTherapeutic exploratory (Phase II)
A phase II randomised trial investigating the benefit of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy for resectable NSCLC (ADIL)
This study looks at non-small cell lung cancer that can be treated with surgery. Researchers want to find out if having an immunotherapy drug called Imfinzi after surgery helps stop the cancer from returning, following initial chemo-immunotherapy before surgery. It aims to see if extra treatment improves long-term health.
For: Non Small Cell Lung Cancer (NSCLC)Sweden · Norway · Denmark - RecruitingTherapeutic exploratory (Phase II)
RADIANCE Radiochemotherapy +/- Durvalumab for locally-advanced Anal Carcinoma; A multicenter, randomized, phase II trial of the German Anal Cancer Study Group
This study tests whether adding an immunotherapy medicine called durvalumab to standard chemotherapy and radiotherapy helps treat stage 2 and 3 anal cancer. Doctors want to see if this combination stops the cancer from returning, lowers the need for stoma surgery, and helps people live longer, healthier lives.
For: locally-advanced Anal Carcinoma, Anal cancer stage II and IIIAustria · Germany - AuthorisedTherapeutic exploratory (Phase II)
IFCT-2501 IDEATION ctDNA-guIDEd consolidATION immunotherapy after chemoradiotherapy in patients with stage III non-small cell lung cancer
This study looks at an immunotherapy medicine called Imfinzi for people with stage 3 non-small cell lung cancer. It explores whether using special blood tests to look for tiny traces of tumour DNA can help doctors guide treatment after chemoradiotherapy, aiming to stop the cancer from returning.
For: Stage III Non Small Cell Lung CancerFrance - AuthorisedTherapeutic confirmatory (Phase III)
Durvalumab after concurrent platinum/etoposide chemotherapy and high-dose twice-daily thoracic radiotherapy in limited stage small cell lung cancer – an open label, randomized phase III trial (DAHRTS)
This phase 3 trial looks at whether an immunotherapy drug called durvalumab helps people with limited-stage small cell lung cancer live longer. It tests if giving durvalumab through a drip after standard chemotherapy and radiotherapy helps keep the cancer from returning.
For: Small-cell lung cancer, limited stageDenmark · Finland · Estonia - RecruitingTherapeutic exploratory (Phase II)
A Phase II, Non-comparative, Open label, Multi-centre, International Study of MEDI4736, in Patients with Locally Advanced or Metastatic Non‑Small Cell Lung Cancer (Stage IIIB-IV) who have received at least Two Prior Systemic Treatment Regimens Including One Platinum-based Chemotherapy Regimen (ATLANTIC)
This study is looking at a new medicine called IMFINZI for people in the UK with advanced lung cancer who have already had at least two different treatments. It wants to see how well the medicine shrinks tumours and helps people live longer, while also checking for any side effects.
For: Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIBIV)Belgium - RecruitingTherapeutic exploratory (Phase II)
A phase II trial of radiotherapy-durvalumab without prophylactic neck irradiation in squamous cell carcinoma of the head and neck (REWRITe)
This study is looking at a new way to treat head and neck cancer. It combines standard radiotherapy with a new drug called durvalumab, and aims to see if we can reduce the need for surgery in the neck, while still controlling the cancer.
For: Untreated squamous cell carcinoma of the head and neckFrance - RecruitingTherapeutic exploratory (Phase II)
IFCT-1802 SAVIMMUNE A phase II single-arm trial evaluating safety and efficacy of Durvalumab in ECOG Performance Status 2-3, treatment-naive, patients with stage IV Non-Small Cell Lung Cancer (NSCLC) and high PD-L1 tumor expression
This study looks at a new cancer treatment called durvalumab (Imfinzi) for people with a type of advanced lung cancer. It aims to see how safe the treatment is and if it helps people feel better. It focuses on patients who are quite unwell at the start.
For: Non small cell lung cancer, Poor general statusFrance - RecruitingPhase I and Phase II (Integrated)- Other
A phase I/II multicenter trial evaluating the association of hypofractionated stereotactic radiation therapy and the anti-PD-L1 Durvalumab (Medi4736) for patients with recurrent glioblastoma
This study looks at combining a new type of radiation therapy with a drug called Durvalumab (Imfinzi) for people with a brain tumour called glioblastoma that has come back. It aims to see if this treatment is safe and if it helps people live longer.
For: Recurrent glioblastoma.France - RecruitingTherapeutic exploratory (Phase II)
Thoracic Radiotherapy plus Durvalumab in Elderly and/or frail NSCLC stage III patients unfit for chemotherapy - Employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy
This study looks at a new way to treat lung cancer for older or frailer patients. It combines a special type of radiation therapy with a drug called durvalumab (Imfinzi). The aim is to see if this treatment is safe and effective in shrinking tumors in people who can't have standard chemotherapy.
For: unresectable stage III NSCLC (Non–small-cell lung cancer)Germany - RecruitingPhase I and Phase II (Integrated)- Bioequivalence Study
MOVIE_A phase I/II basket trial evaluating a combination of Metronomic Oral Vinorelbine plus anti-PD-L1/anti-CTLA4 ImmunothErapy in patients with advanced solid tumours.
This study looks at a new combination treatment for advanced cancers. It combines a low, regular dose of vinorelbine (a chemotherapy drug) with two immunotherapy drugs (durvalumab and tremelimumab), aiming to find the safest dose and see how well it works.
For: Patients with locally advanced or metastatic solid tumoursFrance - AuthorisedTherapeutic exploratory (Phase II)
Phase II, clinical trial, to evaluate OS in two cohorts in relapsed stage III non-small-cell lung cancer (NSCLC) pretreated with chemoradiotherapy and durvalumab
This study is looking at a new treatment called IMFINZI for advanced lung cancer. It wants to see if IMFINZI can help people live longer, especially those whose cancer has come back after other treatments. The study is also checking if the treatment is safe and how well it works.
For: NSCLC non-small cell lung cancerItaly - AuthorisedTherapeutic exploratory (Phase II)
An Open-label, Single-arm, Global Study of Perioperative Durvalumab With Cisplatin-based Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)
This study looks at a new treatment called Durvalumab (IMFINZI) combined with chemotherapy before surgery for bladder cancer. Researchers want to see if this combination causes any serious side effects and how well it works in patients with muscle-invasive bladder cancer.
For: Patients With Muscle-Invasive Bladder CancerItaly · Spain · France